{
    "id": "31291294",
    "text": "MT-45 (IC-6) is an opioid analgesic drug invented in the 1970s by Dainippon Pharmaceutical Co. It is chemically a 1-substituted-4-(1,2-diphenylethyl)piperazine derivative, which is structurally unrelated to most other opioid drugs. Racemic MT-45 has around 80% the potency of morphine, with almost all opioid activity residing in the (S) enantiomer (the opposite stereochemistry from the related drug lefetamine). It has been used as a lead compound from which a large family of potent opioid drugsUS Patent 4080453 have been developed, including full agonists, partial agonists, and antagonists at the three main opioid receptor subtypes. Recreational use of MT-45 has been associated with hearing loss and unconsciousness. MT-45 became a class A drug in the UK on 11 March 2015 MT-45 is banned in the Czech Republic. The Canadian Controlled Drugs and Substances Act was amended in 2016 to include the substance as a Schedule I substance. Possession without legal authority can result in maximum 7 years imprisonment. Further, Health Canada amended the Food and Drug Regulations in May, 2016 to classify MT-45 as a restricted drug.Regulations Amending the Food and Drug Regulations (Parts G and J \u2014 Lefetamine, AH-7921, MT-45 and W-18) Only those with a law enforcement agency, person with an exemption permit or institutions with Minister's authorization may possess the drug in Canada. In the United States the DEA placed MT-45 in Schedule 1 of the Controlled Substance Act. This took effect January 12, 2018. ==See also== * AH-7921 * AD-1211 * Diphenidine * Diphenpipenol * Ephenidine * Fluorolintane * IC-26 * Lanicemine * Lefetamine * Methoxphenidine (MXP) * Metonitazene * Remacemide == References == Category:Synthetic opioids Category:Piperazines Category:Mu-opioid agonists Category:Diarylethylamines Category:Designer drugs ",
    "title": "MT-45"
}